Treatment compliance of patients with paracoccidioidomycosis in Central-West Brazil

• Autor(a) principal: Andrade, Ursulla Vilella
• Data de Publicação: 2019
• Outros Autores: Oliveira, Sandra Maria Do Valle Leone De, Chang, Marilene Rodrigues, Pereira, Edy Firmina, Marques, Ana Paula Da Costa, Carvalho, Lidia Raquel De, Mendes, Rinaldo Poncio, Paniago, Anamaria Mello Miranda
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Repositório Institucional da UNESP
• Texto Completo: http://dx.doi.org/10.1590/1806-3713/e20180167; http://hdl.handle.net/11449/183789
• topic: Paracoccidioidomycosis; Treatment adherence and compliance; loss to follow-up; mycoses; Paracoccidioidomicose; Cooperação e adesão ao tratamento; perda de seguimento; micoses

ABSTRACTObjective: To evaluate the treatment compliance of patients with paracoccidioidomycosis.Methods: We studied 188 patients with paracoccidioidomycosis admitted to a tertiary referral hospital in the Central-West Region of Brazil from 2000 to 2010, to assess their compliance to treatment. In order to be considered compliant, patients needed to present two established criteria: (1) receive medicines from the pharmacy, and (2) achieve a self-reported utilization of at least 80% of the dispensed antifungal compounds prescribed since their previous appointment.Results: Most patients were male (95.7%), had the chronic form of the disease (94.2%), and were treated with cotrimoxazole (86.2%). Only 44.6% of patients were treatment compliant. The highest loss to follow-up was observed in the first 4 months of treatment (p < 0.02). Treatment compliance was higher for patients with than for those without pulmonary involvement (OR: 2.986; 95%CI 1.351-6.599), and higher for patients with than without tuberculosis as co-morbidity (OR: 2.763; 95%CI 1.004-7.604).Conclusions: Compliance to paracoccidioidomycosis treatment was low, and the period with the highest loss to follow-up corresponds to the first four months. Pulmonary paracoccidioidal involvement or tuberculosis comorbidity predicts a higher compliance to paracoccidioidomycosis therapy.